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ThE acquired immunodeflciency syndrome
(AIDS) is a clinically multifaceted disease
induced by infection with the human immuno-
deficiency virus (HIV). HIV infection results in a
complex pattern of immunologic alterations that
leads to the development of AIDS in the majority
of HIV seropositive (HIV+) individuals. The
reduction in CD4 T lymphocyte counts is the
hallmark of IHV infection; nevertheless, long
before the reduction in CD4 counts reaches
critical levels, a series of profound and complex
defects that impair the function of CD4 T lym-
phocytes can be detected. Thus, HIV infection is
characterized by quantitative and qualitative
defects affecting CD4 T lymphocytes. It was sug-
gested recently that programmed cell death
(PCD) is an important mechanism leading to
CD4 depletion in IHV infection, and that suscept-
ibility of peripheral lymphocytes to PCD is dif-
ferentially regulated by diverse cytokines. Thus,
type 1 cytokines would protect CD4 lymphocytes
against PCD, whereas type 2 cytokines would not
protect against, and could augment, PCD. We
suggest that the qualitative alterations of the
immune response provoke the CD4 depletion
characteristic of HIV disease via type 2 cytokine-
mediated augmentation of PCD, and are there-
fore ultimately responsible for the progression
of IHV infection. Finally, we summarize recent
data showing that three correlates of disease
progression: emergence of HIV strains with syn-
citium-inducing ability (SI), type 1-to-type 2
cytokine shift, and CD4 depletion, are signifi-
cantly associated, suggesting a complex inter-
connected virologic-immunologic pathogenesis
of HIV infection.
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Defective interleukin-2 production as the
hallmark of qualitative lymphocyte
defects in HIV infection
Early and complex T helper (Th) cells defects
have been described in HW infected indivi-
duals.1-6 We have analysed the qualitative defects
of HW infection by examining in vitro antigen-
and mitogen-stimulated interleukin (IL)-2 produc-
tion by PBMC of H1V+ individuals. PBMC were
stimulated in vitro with recall antigens (influenza
virus, tetanus toxoid, or HIV peptides); HLA
alloantigens (ALLO); or phytohaemagglutinin
(PHA). These stimuli were chosen because they
activate different Th-antigen presenting cell
(APC) pathways,
7 allowing for a more complete
evaluation of the immune system. Thus, recall
antigens are exclusively presented by self-APC to
autologous CD4; HLA alloantigens can be pre-
sented by self-APC to autologous CD4 or they
can be directly recognized by autologous CD4
and CD8 T lymphocytes on the surface of allo-
geneic APC; whereas PHA stimulation of T lym-
phocytes is only marginally dependent on
processation and presentation by APC (see Table
1).
7
The stimulation of PBMC with this panel of
antigens allowed us to recognize that only a
minority (40%) of HIV+ asymptomatic
patients can respond by IL-2 production to recall,
ALLO and PHA.5 Thus, a complex pattern of
defects in IL-2 production was observed in the
majority of HIV+, asymptomatic individuals.
Indeed, approximately 40% of these individuals
showed a selective defect in IL-2 production in
response to recall antigens, whereas 10% of
them could only respond to PHA, or could not
produce IL-2 in response to any stimulation
( 10%).5 Because all these patients were in the
same clinical stage (Walter-Reed stage 1), and
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Table 1. Pathways of T helper cell activation
Antigen T helper Antigen IL-2
cell presenting cell production
with improved T lymphocyte function, but
independent of variations in CD4 counts.
Recall antigens CD4+ self APC ++
HLA alloantigens CD4+ self APC ++
CD4+ allo APC +++
CD8+ allo APC ++
PHA-stimulated IL-2 production is marginally dependent on processation
and presentation by APC.
The type 1/type 2 hypothesis of HIV
infection
In the late 1980s it was shown by different
investigators that murine T helper cells can be
functionally distinguished in two subsets which
are differentially specialized in furnishing pre-
ferential help to cytotoxic T lymphocytes (CTL)
had comparable CD4 counts (>400mmc) the or B lymphocytes.4-7 These two sub-popula-
observed functional defects were not secondary tions, named T helper 1 (TH1) and T helper 2
to a decrease in CD4 counts.5 These experi- (TH2), respectively, were subsequently described
ments allowed us to conclude that: (1) defective in humans by Romagnani.8’9 It was suggested
ability to produce IL-2 can be detected even in recently that some phenotypic markers may allow
the earlier, asymptomatic phases of H1V infec- us to differentiate TH1 and TH2 lymphocytes.
tion; and (2) these defects are not secondary to Thus, it was reported that TH2 lymphocytes may
either a decrease in CD4 counts or a clinical express higher quantities of CD30,iOas well as of
progression in H1V infection. Similar analyses in a particular isoform of BB-7 (BB-7.2). A third
vertically transmitted paediatric H1V infection group has observed that CD4+CD7+ T lym-
showed that: (1) defective IL-2 production is phocytes preferentially secrete TH1 cytokines,
observed also in the majority of H1V+ paedi- whereas CD4+CD7-- T lymphocytes pre-
atric patients;
8 and (2) defective in vitro ferentially produce TH2 cytokines. Nevertheless,
antigen- and mitogen-stimulated IL-2 produc- no marker has yet been identified that exclusively
tion is associated in paediatric HIV disease with clusters on TH1 or TH2, and the definition of
an augmented incidence of opportunistic and TH1 and TH2 lymphocytes is still essentially
bacterial infections.
8 In the attempt to analyse based on the different cytokines that are pro-
whether the defective element is the T lympho- duced by these cells. Thus, TH1 responses are
cyte or the antigen presenting cell, we performed characterized by secre{ion of interferon (IFN)q,
experiments in which cells of HIV-discordant and IL-2 and subsequent promotion of cell medi-
monozygotic twins were matched. The results ated immunity (CMI), whereas TH2 responses
repeatedly indicated the absence of defects in the are characterized by secretion of IL-4 and IL-5,
ability of H1V+ APC to process and present with subsequent activation of humoral immunity
antigens.9’m and generation of antibodies. Interestingly, TH1
We subsequently verified whether defects in and TH2 are cross-regulating as IFN-, suppresses
IL-2 production could be reverted by treatment the activation of TH2 lymphocytes, whereas IL-4
with antiretroviral drugs. Thus, we measured in suppresses the production of TH1 cytokines.
vitro stimulated T lymphocyte proliferation and IL-2 is a prototypical product of TH1 lympho-
IL-2 production in two cohorts of HIV+ adults cytes, and IL-2 production can be down-regulated
and one cohort of paediatric patients, treated by TH2 cytokines (classically IL-4). Thus, we
with zidovudine, sCD4-IgG or ddI respectively, began exploring the possibility that the defective
We observed that all three compounds were IL-2 production observed in HIV+ asymptomatic
capable of temporarily restoring IL-2 produc- infection could be accompanied by augmented
tion independently of any variation in CD4 IL-4 production. We decided to analyse cytokine
counts.-
That this is not an aspecific effect of production by whole PBMC and not by CD4 + T
all antiretroviral drags was shown by a fourth cell clones because we believe cytokine produc-
compound, which was not able to restore T tion by whole PBMC to be a more important
22 231. lymphocyte proliferation or IL-2 production (M. approximation to the in vivo situation. In fact,
Clerici et al., unpublished observations). Addi- even if T cell clones are an important experi-
tionally, the in vitro restoration of IL-2 produc- mental tool, we were concerned about the arte-
tion by antigen- or mitogen-stimulated peripheral facts present in the cloning methodology. Our
blood mononuclear cells provoked by ddI was concerns about clones can be summarised as
associated in paediatric HIV infection with a follows: (1) Th cell cloning results in the loss
significant reduction of o2POrtunistic infections (during the cloning process) of important, non-T
during clinical follow-up. Again, the positive accessory cells that produce cytokines with
changes in clinical parameters was associated immunoregulatory properties, (2) cloning may
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Table 2. TH1 and TH2 cytokines are clonally
defined; type and type 2 cytokines are
functionally defined
TH1 cytokines TH2 cytokines
Interferon 7 Interleukin-4
Interleukin-2 Interleukin-5






subset of HIV+ asymptomatic patients showing
defective IL-2 generation in response to recall
antigens.
24 Similarly, IL-4 mRNA was detected in
PHA stimulated PBMC of HIV+ individuals, but
not in unstimulated PBMC of the same indivi-
duals, or in HIV-- controls.24 Even more impor-
tant, IL-4 neutralizing antibodies were capable to
restore in vitro antigen-stimulated proliferation
and IL-2 production in the majority of patients
secreting high amounts of IL-4.
24
Because IL-10 was described as able to sup-
press the secretion of type 1 cytokines and CMI
even more powerfully than IL-4, we next decided
to measure IL-10 production in HIV+ asympto-
matic patients. Similarly to the methods used to
select for populations of T cells, as the techni- generate IL-4, we stimulated PBMC in vitro with
ques involve the selection and expansion of cells PHA for 48 h; the amount of IL-10 produced was
in relatively high concentrations of IL-2; and (3) measured using commercially available ELISA kits,
the investigation of PBMC tests for the effects of and IL-10 mRNA was quantified using PCR
cytokines produced by multiple cell types on Th methods. We observed that IL-10 production was
cell function, and includes both autocrine and augmented in H1V+ asymptomatic patients
paracrine regulation whereas in cloned T cell showing defective IL-2 production, and that the
tests for the cytokines produced by these clones patients with the most severe defective IL-2 pro-
is limited to autocrine regulation. Because our duction (i.e. inability to generate IL-2 even in
obseeeations were based on cytokine production response to PHA) generated the highest quan-
by all the cells circulating in the peripheral blood tities of IL-10.25 By analogy to what was obseeeed
and not on clonal isolation, we decided to for neutralizing antibodies to IL-4, in vitro
identi the cytokine patterns obseeeed as type 1 antigen-stimulated proliferation and IL-2 produc-
(mainly CMI-inducing), and type 2 (mainly tion could be restored in the majority of these
humoral immunity-inducing).22’2-3- Because we patients by neutralizing antibodies to IL-10.25
defined cytokines on a functional basis, we could Similarly, we could restore in vitro antigen-stimu-
enlarge the group of type 1 cytokines to include lated proliferation and IL-2 production, as well as
It-12 and, probably, IL-15 (all cytokines that mitogen-stimulated IFNq, production, by IL-12,
26
mainly stimulate CMI, but are not mainly or a prototypical type-1 cytokine described by
exclusively produced by clones of CD4+ T lym- Chehimi et al. as defective, even in the earlier
phocytes) in addition to IL-2 and IFNq,. Similarly, phases of HIV infection,iv Thus, we proposed
IL-6, IL-10 and probably IL-13 were considered to that HIV infection is associated with the pro-
be type 2 cytokines even if they are produced by gressive impairment of type 1 cytokine produc-
cells other than CD4 + T lymphocytes, as their tion, and the progressive augmentation of type 2
main effect is that of stimulating B cell activity cytokine secretion.22’23 It is important to under-
and antibody generation (see Table 2). line that these events are observed in the asymp-
To measure IL-4, we stimulated PBMC of tomatic phase of HIV infection, before the
HIV+ asymptomatic donors in vitro with PHA development of full blown disease. These data,
for 48 to 72h, as suggested by kinetic studies, confirmed by numerous other authors,
28-37 are
and we evaluated the amount of IL-4 present in the experimental basis of the type-I/type-2
the supernatants using a cell line (a kind gift of hypothesis of HIV infection.
Dr William Paul, NIAID, NIH) whose growth is Because cytokine secretion is associated with a
dependent on IL-4. (To simplify the assay, we are quantity of diverse biological effects which are
now measuring IL-4 using commercially available readily measurable, we suggest that the list of
ELISA kits.) To analyse the production of IL-4 at these effects, which are frequently observed in
the molecular level, we also quantified (in colla- HIV+ patients and are presented in Table 3,
boration with Dr Thomas Wynn, NIAID, NIH) the strongly support the hypothesis of a profound
expression of IL-4 mRNA in the PBMC of the cytokine imbalance in HIV infection. Thus, the
same patients. We observed that IL-4 production impairment of delayed type hypersensitivity reac-
was greatly augmented in PHA-stimulated super- tion is secondary to defective IFN-,, IL-2 and IL-
natants of HIV+ individuals as compared to 12 production, whereas hyper-IgE is secondary to
HIV-- controls, and that the increased IL-4 pro- the augmented production of IL-4, and hyper-
duction was most likely to be observed in the eosinophilia is secondary to the augmented pro-
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Table 3. Unfavourable prognostic signs in HIV infection
Decreased production of type cytokines (IFN-7, IL-2, IL-12)
Increased production of type 2 cytokines (IL-4, IL-5, IL-6, IL-10)
Reduced delayed type hypersensitivity (DTH) reactions
IL-4-driven hyper-lgE
IL-5-driven hypereosinophilia
duction of IL-5. All these parameters are ore-
dictors of poor prognosis in HIV infection.3"8-46
Interestingly, it has recently become evident that
defective in vitro antigen- and mitogen-stimulated
IL-2 production is predictive for subsequent
reduction in CD4 counts, the time to acquired
immunodeficiency syndrome (AIDS), and time to
death.47
Different patterns of disease progression
in HIV infection
Higher CD4 counts, better preserved IL-2
secretion, and the absence of the clinical signs of
type 1/type 2 cytokine imbalance listed in Table
3 are associated with a lack of progression of
HIV infection. It has recently become evident
that, although the vast majority of HIV+ indivi-
duals progress to AIDS, a minority of HIV+
patients exists that does not develop AIDs or
show a critical reduction in CD4 T cells, despite
long-lasting infection with HIV.
48 These patients
have recently been defined long-term non-pro-
gressors (LTNP). Different groups have focused
on diverse aspects of this phenomenon, the solu-
tion of which holds the possible key to a cure
for AIDS. Two biological interpretations can be
offered in the attempt to explain long-lasting HIV
infection without AIDS. Thus, these patients may
have been infected by a defective, less patho-
genic HIV variant, or these patients may have a
stronger immune response, capable of keeping
HIV under control. More likely, a strong immune
response is preventing HIV from becoming
frankly virulent in these individuals. In support of
this hypothesis are the findings by Ho and col-
leagues, and Fauci and colleagues indicating that
strong H1V-specific CTL were observed in two
groups of LTNP.49’5 Additionally, it was recently
shown that: (1) preserved T cell function corre-
lates with stable CD4 counts;
51 (2) disease-free
survival correlates with gag-specific cytotoxic T
lymphocyte activity;52’53 and (3) HIV infected
chimpanzees become seropositive but do not
progress toward AIDS.54 Finally, it has recently
been verified that neither a type 1-to-type 2 cyto-
kine shift nor programmed cell death are present
55 56 in HW+ chimpanzees.
We have recently analysed (in collaboration
with the Clinica delle Malattie Infettive, Universitt
di Milano) cytokine production in a group of
LTNP, and compared the cytokine profile with
that observed in a group of patients with pro-
gressive HIV infection. As we expected, a strong
type 1/weak type 2 cytokine profile was observed
in the LTNP, whereas a symmetrically opposite
weak type 1/strong type 2 cytokine profile was
observed in patients with progressive HW infec-
tion.57 Interestingly, a significantly increased per-
centage of CD4+/CD7-- T lymphocytes (as
remembered above, CD4 +/CD7-- T lympho-
cytes predominantly secrete type 2 cytokines)
was observed in the individuals with progressive
HIV infection, but not in the LTNP.57
We have performed (in collaboration with the
Cattedra di Pediatria IV, Universitt di Milano)a
second study in a cohort of vertically infected
children with different patterns of disease pro-
gression. In fact, HIV vertical infection follows a
bimodal pattern according to which 20% of verti-
cally infected children develop MDS and even-
tually die within the first year of life, whereas the
remainder develop MDS at a constant rate per
year, reaching the median at about 5 years after
birth.58 We have thus studied a group of verti-
cally infected HW+ children who did not
develop AIDS within the first year of life, and we
identified two subsets of children of comparable
age, the first one of which was asymptomatic,
while the second one showed severe signs of
H1V disease. The results indicated that, despite
the presence of severe defects in type 1 cytokine
production in both groups of children, a greatly
increased type 2 cytokine secretion was char-
acteristic of the symptomatic, but not of the
43 t n asymptomatic children. In eresti gly, a sig-
nificant association with hyper-IgE (the produc-
tion of which is stimulated by IL-4 secretion) was
observed in the paediatric cohort.43 Thus, we
suggest that a strong type 1/weak type 2 cytokine
production is associated with delayed (or absent)
progression of H1V infection to MDS.
Susceptibility of T lymphocytes to
programmed cell death (PCD)is
differentially regulated by type 1 and
type 2 cytokines
It has been observed that PCD is increased in
HIV infection, and it was thus suggested that PCD
could be one of the mechanism(s) primarily
responsible for CD4 depletion in the progression
tO AIDS.59’6 HIV+ lymphocytes undergo PCD in
unstimulated conditions, and much more so
6O 61 when stimulated with mitogens. One of the
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major differences between H1V+ and H1V-- lym- tropism for different cell lines, and the capacity
phocytes is that whereas only mitogen-activated to induce the formation of syncytia in vitro.62-6
HIV- lymphocytes (blasts) will undergo PCD To verify whether the isolation of syncytium-
upon a second mitogenic restimulation, even inducing H1V is correlated with the type 1-to-type
resting (unstimulated) HIV+ PBMC will undergo 2 cytokine shift, we have analysed virologic and
PCD upon stimulation. Therefore, two serial in immunologic parameters in two groups of HIV
vitro stimuli are needed to induce PCD in HIV-- vertically infected children of comparable age
lymphocytes, whereas a single in vitro stimulation who have or have not progressed to AIDS. We
will provoke PCD in HIV+ lymphocytes, suggest- observed that progression to AIDS in paediatric
ing that in H1V infection lymphocytes are pre- H1V infection is associated with isolation of HIV
activated in vivo to undergo PCD upon in vitro SI variants and increased production of the type
restimulation.’ 2 cytokines IL-4 and IL-10. Additionally, we
Mitogenic stimulation will activate CD4 and observed that these two parameters are statisti-
CD8 lymphocytes via T cell receptor-mediated cally associated and that extensive CD4 loss is
stimulation, inducing PCD in both subsets of T associated both with the isolation of SI variants
lymphocytes. It was recently obseeeed that PCD and increased IL-4 production (M. Clerici et al.,
is differentially regulated by type 1 and type 2 submitted). These recent data indicate that the
cytokines. Thus, PCD was prevented in vitro by virologic and immunologic parameters character-
IFN-7, IL-2 and IL-12 whereas PCD was not pre- istic of advanced H1V infection are strictly asso-
vented, or was augmented, by IL-4 and IL-10. ciated, and strongly support a virologic-
Even more relevant was the observation that PCD immunologic pathogenesis leading the appear-
could be prevented by neutralizing antibodies to ance of AIDS.
type 2 cytokines, but could not be prevented, or
was even raised by neutralization of type 1 cyto-
kines.2 We have recently obseeeed that the Cnluin
selective stimulation of CD4+ lymphocytes by
recall antigens will induce PCD exclusively in the We suggest that the complex qualitative altera-
CD4 subset, a situation that more closely resem- tions observed in HW infection are responsible
bles that observed in viva Even in this situation, for the progression of HIV disease to AIDS, and
PCD was oppositely modulated by type 1 and that the dramatic reduction of CD4 T lympho-
type 2 cytokines, or by the neutralization of type cytes which is the hallmark of this disease is
1 or type 2 cytokines. Additionally, we verified mainly secondary to phenomena of PCD that is
that PCD is effected by lymphotoxin, and that increased by a type 1/type 2 cytokine imbalance.
lymphotoxin is responsible for a soluble-factor Thus, we suggest that every therapeutic
mediated amplifying loop which causes PCD in approach to HIV infection should consider the
innocent-bystander lymphocytes. Finally, the necessity to restore the normal functionality of
PCD-inducing effect of lymphotoxin is differen- the immune system. These approaches could at
tially influenced by type 1 and type 2 cytokines least theoretically be based on the utilization of:
(m. Clerici et al., submitted). We suggest that the (1) type 1 cytokines; (2) antibodies neutralizing
impaired production of type 1 cytokines and the type 2 cytokines; or (3) pharmacological com-
augmented generation of type 2 cytokines char- pounds aimed at the selective stimulation of
acteristic of H1V infection results in the destruc- type 1 cytokine secretion and subsequent aug-
tion of CD4 lymphocytes, which is increased by mentation of CMI. It is important to notice that
type 2 cytokines and mediated by lymphotoxin, the results of a first clinical trial based on the
Thus, antigen stimulation of H1V+ lymphocytes utilization of IL-2 have shown significant
in the presence of abnormally low concentra- improvement in CD4 counts (possibly via the
tions of IFN-7, IL-2 and IL-12, and of abnormally prevention of IL-2-induced PCD). Thus, we
elevated concentrations of IL-4 and IL-10 results strongly favour approaches based on the
in the induction of PCD, instead of the induction restoration of normal cytokine production in
of T cell proliferation, the therapy for HIV infection, as we believe that
a strong CMI is associated with better prog-
nosis, and will ultimately be more capable of
Virologic and immunologic correlates of controlling HIV replication and disease progres-
poor prognosis are associated sion.
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